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Abstract
Summary Adherence to anti-osteoporosis medications is
currently low and is associated with poor anti-fracture
efficacy. This manuscript reviews the potential design of
clinical studies that aim to demonstrate improved adherence,
with new chemical entities to be used in the management of
osteoporosis.
Introduction Several medications have been unequivocally
shown to decrease fracture rates in clinical trials. However,
in real life settings, long-term persistence and compliance
to anti-osteoporosis medication is poor, hence decreasing
the clinical benefits for patients.
Methods An extensive search of Medline from 1985 to
2006 retrieved all trials including the keywords osteoporo-
sis, compliance, persistence or adherence followed by a
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critical appraisal of the data obtained through a consensus
expert meeting.
Results The impact of non-adherence on the clinical
development of interventions is reviewed, so that clinicians,
regulatory agencies and reimbursement agencies might be
better informed of the problem, in order to stimulate the
necessary research to document adherence.
Conclusion Adherence to therapy is a major problem in the
treatment of osteoporosis. Both patients and medication
factors are involved. Adherence studies are an important
aspect of outcomes studies, but study methodologies are not
well developed at the moment and should be improved.
Performing adherence studies will be stimulated when
registration authorities accept the result of these studies
and include the relevant information in Sect. 5.1 of the
summary of product characteristics. Reimbursement au-
thorities might also consider such studies as important
information for decisions on reimbursement.
Keywords Adherence . Compliance . Persistence .
Registration . Reimbursement
Introduction
Effective treatments for postmenopausal osteoporosis have
been available now for more than 10 years. Large well-
controlled randomized clinical trials (RCTs) have shown that
interventions decrease vertebral fracture risk by about 50%.
Significant effects of some treatments on non-vertebral
fractures have also been shown, though the effect size is
often smaller. Despite this clear demonstration of a thera-
peutic benefit, several observational studies have shown that
efficacy is much lower in patients that are incompletely
adherent to their therapy. A number of studies have shown
that up to 50% of patients no longer adhere after the first year
of therapy and that poor persistence and compliance are
associated with higher fracture rates. Estimates include a
19–36% higher fracture risk with a compliance of less than
80% [1–6]. The most detailed analysis described a dose-
dependency for persistence on fracture risk [2]. Fracture
rates were stable until compliance as judged by the medical
possession ratio (MPR, see later) fell below about 50%.
Similarly, treatment-induced increases in BMD were less in
poorly compliant patients. In patients with compliance rates
of < 66%, BMD increased by 2.8% over 1 year at the
lumbar spine, whereas BMD increased by 3.8% in patients
with the higher compliance rates. Thus, as noted in a recent
comment in the Lancet, compliance with osteoporosis
therapy is the weakest link [8].
This phenomenon is not unique for osteoporosis, and it
has been shown for other interventions in other chronic
diseases such as hypercholesterolaemia, heart diseases as
well as for the combined antiretroviral treatment for HIV. In
general adherence is a particular problem in chronic
asymptomatic conditions [9, 10].
Against this background, GREES organized a meeting to
discuss the impact of non-adherence on the clinical develop-
ment of interventions for the management of osteoporosis, so
that clinicians, regulatory agencies and reimbursement agen-
cies might be better informed of the problem, to stimulate the
necessary research, to document adherence, and, perhaps, to
investigate the manner by which adherence could be
improved. The meeting was informed by a literature search
aimed to identify all papers relating to adherence in the
prevention or treatment of osteoporosis. A search of Medline
using a predefined strategy was made in September 2006.
An additional search was made of abstracts in relevant
journals over the previous three years. No language, date or
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lists of relevant articles were hand searched and sifted by title
for relevance, and thereafter by the full publication.
Defining adherence
When studying adherence there is a need for precise
definition of the terminology that will be used. In the
literature there is a wide variety of definitions. A term
commonly used is compliance, but it has been argued that
the term implies “obedience”. This has resulted in alterna-
tive terminology that also infers the active choice of the
patient [11, 12], such as adherence [13], patient cooperation
[14], therapeutic alliance [15] or concordance [16]; terms
that capture the agreement between patient and physician.
For these reasons, it is important to provide definitions. The
authors favour the use of the terms adherence, persistence
and compliance, which are defined below and are in line
with the definitions issued by the International Society for
Pharmacoeconomic and Outcomes Research (ISPOR).
Adherence General term encompassing all aspects men-
tioned below.
Persistence For how long the medication is taken. Persis-
tence could be expressed as the number of days until drop-
out or the proportion of the cohort still on medication after
a given time since first prescription. Non-persistence is
assumed to be the same as discontinuation if a treatment
gap is longer than a set number of days.
Compliance Proximity to the treatment recommendations
as given in the official product information (SPC). It is
often simplified to mean the number of doses taken divided
by the number of prescribed doses. This simplification does
not include some important aspects of compliance, such as
taking medication with food (for the oral bisphosphonates),
at the correct time of the day, too large doses to compensate
for forgotten doses, pill dumping, etc.
Primary non-adherence Where a patient is prescribed a
drug and then never fills the prescription.
Quantifying adherence
Adherence is often quantified as medical possession ratios
(MPR), which usually is defined as the sum of all days of
medication supply received during a given time, say 1 year,
divided by the 365 potential days of supply. The value of the
MPR is limited in that it does not provide insight into
consistency of refilling or whether a drug is being taken as
described. The MPR is, in effect, a mixture of persistence
and adherence and any improved outcomes associated with a
higher MPR may be, to some extent, because those patients
take their drugs for a longer time, i.e., are more persistent.
The literature often blurs the distinction between non-
persistence and discontinuation, but the two concepts are not
necessarily equivalent. An individual who is non-persistent
may have a gap in treatment, but may resume medication at
some point in the future. If treatment is stopped, but restarted,
a patient may be considered to be non-persistent, depending
upon the drug-free interval. What is an acceptable ‘grace
period’ varies between studies and ranges from 2 weeks [17,
18] to 2 months or more [7, 19–21], but is often not
specified. In general, the longer the defined grace period, the
higher the adherence rates. For example, in a study
comparing alendronate and ibandronate, persistence was
judged to be 38% and 56%, respectively, when allowing a
two-week grace period, though at 6 months, 73 and 80% of
patients had refilled 5 of the 6 monthly prescriptions [18].
It is also relevant to note that persistence rates depend
upon whether a single agent or multiple agents are
considered. Persistence with a specific agent does not take
account of switching treatments. The available data suggest
that a substantial minority of patients switch from one to
another agent. Estimates of switching of osteoporosis
treatment vary between 11%, and 31% [17, 22, 23]. These
difficulties in the assessment of persistence emphasise the
complexity of measuring adherence accurately and argue
for a minimum standard for the reporting of adherence.
Pattern of adherence
The heterogeneity in reporting adherence rates impedes
meaningful comparisons between studies. Greater reliance
can be placed on comparisons made within studies, for
example comparisons of bisphosphonates given daily or
weekly.
Adherence typically decreases with time, particularly in
the first treatment year. For instance in one study 47% of
the patient did not adhere after 3 months, 70% after
12 months [7]. For persistence, several long-term studies
indicate that this remains stable thereafter for 5 years or
more [2, 21]. For compliance, rates fall over two years and
then remain stable. The absolute levels of persistence and
compliance are more difficult to assess because of differ-
ences in reporting. Although several studies show low
persistence, in the order of 20–50%, many studies show
persistence rates that are rather similar to those reported in
randomised controlled trials. In particular, those from the
UK show rates on the order of 80% [18, 22, 24, 25]. The
lowest rates reported are from North America where in
some studies, low persistence may reflect the lack of an
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affordable treatment for some patients, known to be an
important factor in non-persistence.
There are fewer studies of compliance and nearly all are
from North America. Estimates vary from 47–70%.
Compliance may be higher with weekly compared with
daily administration of bisphosphonates [20]. In a large US
managed-care database, with a follow-up of up to 5 years,
three-quarters of patients had an MPR below 80% and 53%
had a compliance below 50% [2]. This figure included,
however, patients who became non-persistent. When
account is taken of non-persistence, compliance in patients
taking medication is higher as judged by MPR [2, 26].
The determinants of adherence
Poor adherence is a particular problem in chronic asymp-
tomatic conditions [9, 27]. The causes for non-adherence
are poorly understood; in principle they can be patient-
dependent (age, education, motivation) or medication-
dependent (dosage regime or frequency of administration,
special precautions taking the medicine). In addition, the
physician-patient relationship, physician training, nurse-led
programs and patient education can be important factors in
adherence [28, 29]. Few studies have investigated predic-
tors for non-adherence, as has been done for AIDS
treatment [30]. Determinants of low persistence and
compliance in the context of osteoporosis include side
effects, poor general health, the absence of a prior fracture,
old age, not being engaged in social activities and fracture
early during treatment [1, 2, 23, 31]. A major perceived
problem with the oral bisphosphonates is the inconvenience
of the regimen, and there is a well established association
between complex dosing regimens and compliance [32]. A
survey in the UK cited inconvenience, the belief that the
drug would stop working and concern over drug-
dependence as major determinants of non-persistence [33].
In multivariate analyses, however, these various factors
explain but a minority of non-adherent behaviour [33].
The consequences of poor adherence
As noted above, the consequences of poor compliance
and persistence lie in the reduced effectiveness of
treatment but the quantum is insecure. The most detailed
analysis described a dose-dependency for persistence on
fracture risk [7]. Fracture rates were stable until compli-
ance (excluding non-persistent patients) fell below about 60
to 80% as judged by the medical possession ratio (MPR)
[2, 26].
Although, non-adherence appears to be associated with
major impact on health outcomes, this is caused only in part
by less than optimal medicinal treatment. Non-adherence as
such is a risk factor for lower health outcome. For example,
a placebo controlled study with amiodarone on cardiac
mortality demonstrated that poor adherence to medication
has an negative impact on outcome even in the placebo arm
[34]. This phenomenon has also been demonstrated in
another cardiovascular trial (Charm) with candesartan [35].
In these last two comparative studies, adherence to placebo
resulted, respectively, in a lower odds ratio for death or in a
lower all cause mortality with a hazard ratio of 0.65
compared to non adherent placebo treated patients. Thus,
although these various studies indicate a consistent associ-
ation between poor compliance and reduced effectiveness
of intervention, the association should, however, be
cautiously interpreted since non-compliant patients have
higher co-morbidity rates, are more frail and have higher
health-care expenditure. Some of these studies have
‘adjusted’ for confounding factors, but information on
potential confounders is limited and confined to the few
data available from medical claims [1, 2, 21, 31]. It is
plausible that poorly compliant patients have, therefore,
higher fracture risks before treatment is started. In other
words the association may not be causal, or the quantum
may be overestimated. Indeed, fracture risks have been
reported to be higher and BMD lower in non-persistent
patients taking a placebo compared with persistent patients
in the placebo wing of an intervention study [31].
Improving adherence
Adherence to osteoporosis treatment may be influenced by
inconvenient dosage requirements, e.g., taking oral
bisphosphonates daily at least 30 minutes before breakfast
in an upright position. There are several options for
improving adherence, e.g., nurse-led follow up, education
programs and easier-to-follow medication regimes. The
monitoring of treatment may also have a role, and a
randomised study has suggested that adherence is improved
in women with osteoporosis monitored with the measure-
ment of biochemical indices of bone turnover [36]. In
addition, new formulations and dosages schemes have been
developed which in principle could help to improve
adherence to treatment. For example, a weekly bisphos-
phonate regimen improves persistence of therapy compared
with daily administration [37]. However, even with the
weekly regimen, the benefit for adherence remains sub
optimal indicating a need to further improve adherence.
New options for intermittent treatment are now available,
including monthly oral formulations, quarterly intravenous
injections, six-monthly injections, and yearly infusions are
in development. Weekly and monthly oral bisphosphonate
treatment and monthly and yearly intravenous treatment
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have comparable effects on BMD as daily treatment. If these
new intermittent treatment regimens are as efficacious and
safe as the older regimens, they could have major impact on
persistence. When comparing intermittent with non inter-
mittent regimes it should be clearly defined what is meant by
intermittent therapy and what is the precise objective of the
study. These studies may be difficult to perform; for
example, comparing daily oral treatment with yearly
intravenous infusion treatment requires a long-term study.
Both health authorities and industry are interested in
studies that measure adherence in patient groups taking
different formulations and dosing regimens. Adherence
could have practical pharmaco-economic consequences
and could affect reimbursement decisions. The impact of
poor adherence on cost-effectiveness is not straightforward.
Whereas poor adherence decreases the effect of interven-
tion, this is offset to some extent by a reduction in the cost
of medication. In models of persistence it has been assumed
simplisticly that 20–80% of patients complete a full 5-year
course of treatment, and that the remaining non-persistent
patients receive 3 months of drug treatment for no health
gain [38, 39]. The impact on cost-effectiveness was
relatively small until persistence fell below about 20%.
The problem with this approach is that it does not
reproduce the real world. For example, those that discon-
tinue treatment do so at time points throughout the 5-year
period and should, thus, receive some health benefit and
additional drug costs. More realistic economic models that
capture the complex elements of adherence are required.
Pharmaco-economic evaluation should not be limited to
cost-effectiveness, and social costs are also important
determinants. Industry is interested in these issues because
better adherence to regimens could also be translated in
promotional claims. However, registration authorities will
only allow results of adherence studies to be included in the
official product information if an effect on efficacy and/or
safety has been demonstrated.
How to investigate adherence
Adherence to therapy is different in clinical trials when patients
are intensively followed and treated in a highly structured
environment, as found in phase III studied, compared with
what occurs in daily clinical practice. Clinical trials will
enhance patient behaviour and potentially elevate the observed
compliance and persistence rates. There is a strong preference,
therefore, to study adherence in observational studies that more
closely reflect daily clinical practise [40].
Different study approaches can be envisaged. It is
preferred to perform prospective and comparative studies.
Blinding is problematic, because double dummy studies
will hamper the objective of the study. Retrospective
studies are difficult to interpret because of the risk of
confounding, since they cannot take into account all the
differences in design between studies.
Studies that use databases in which pharmacy data are
combined with hard clinical outcome data, such as
fractures, will certainly be of value. In these studies,
however, persistence but not compliance is measured, and
have, therefore, their limitations.
Both direct and indirect methods for measuring adher-
ence could be used (see Table 1). Direct methods are more
expensive and more labour-intensive. Measurement of inert
markers included in formulations is in theory a possibility
but this is not generally accepted by authorities overseeing
trials. The safety of the marker should be demonstrated and
the marker has to be declared on the label. This could in
turn influence the compliance. Indirect methods seem to be
less accurate and reliable, but there exists a significant
association between the two possibilities [41, 42]. For some
active substances, such as strontium, direct measurements
of drug or its metabolites in biological fluids may be used
as validation of indirect measurement such as pill count.
More pragmatic is the use of indirect methods, but these
methods should be improved. Self reporting by patients is in
principle unreliable. At present, measurement of adherence in
studies of osteoporosis relies mostly on pill counts and self-
reporting [43]. Pill counts and self-reporting overestimate
true compliance [44–49]. In addition, they provide no
information on the patient’s behaviour surrounding drug
intake. Another possibility is the use of electronic monitoring
devices with which patient’s behaviour of drug intake can be
closely monitored. Electronic monitoring of dose intake
potentially offers a useful method for assessing adherence.
The best approach is to generate prospective data in an
open comparative study. A number of problems need to be
resolved when two different products are compared. Co-
payment could influence adherence. Another issue in a trial
situation is that informed consent has to be signed by the
patient. Thus the patient is aware of the objective of the
study which may influence the result. Indeed, any prospec-
tive study in which adherence is a primary end-point is
likely to overestimate adherence in clinical practice and
Table 1 Direct and indirect methods measuring compliance
Direct methods Indirect methods
Measurement of drug or metabolite
in a biologic fluid
Self-reporting by the patient
(interview, diary, questionnaire)
Measurement of efficacy
surrogates (e.g., urinary excretion
of bone markers, BMD)
Medication measurement (pill
count), refill logs (pharmacy)
Direct intake observation Electronic monitoring devices
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may merely replicate information provided by intention-to-
treat analyses of phase III clinical trials. In such studies,
persistence to therapy might be evaluated by measuring
prescription refill dispensed to the patient over the study
period and a patient questionnaire. An electronic pill
counting device could also be used.
A totally different study format is to perform two single-
arm open multi-centre studies each to investigate treatment
satisfaction with therapy with two treatments X and Y as the
primary objective. Scales of treatment satisfaction are now in
development derived from quality of life (QoL) scales.
Persistence to treatment and reasons for discontinuation are
included as secondary objectives. Randomisation could be
done at patient level. However, an interesting alternative
possibility would be randomisation of the prescribing
physician. This latter approach avoids a certain prescribing
confounding and has the advantage of a more naturalistic
design. The patient gets the prescription from his or her
prescriber, and medicines are distributed by their own
pharmacy. There are hardly extra visits necessary. At the end
a meta-analysis in a pre-planned third study is done to
compare the results of the two studies.
Cohort studies that examine persistence and compare
results with historical data are prone to bias and are, thus,
unreliable. For this reason, studies using retrospective data
should be strongly discouraged.
Further investigation is also warranted to better under-
stand the barriers to adherence with medical therapies and
dietary and lifestyle interventions that are important for the
optimal management of osteoporosis.
In conclusion adherence to therapy is a major problem in
the treatment of osteoporosis. Both patient and medication
factors are involved. Many stakeholders are interested in
studying adherence with the objective of improving health
outcomes. Study methods are not well developed at the
moment and should be improved. Performing adherence
studies will be stimulated when registration authorities accept
the results of these studies and include the results in Sect. 5.1
of the SPC. At present, such data would only be included if a
better outcome has been demonstrated. Reimbursement
authorities might be convinced to consider this as important
information for their reimbursement decisions. Adherence
studies are an important aspect of outcome studies.
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